(Total Views: 524)
Posted On: 04/07/2025 1:42:10 AM
Post# of 151733
An automatic Google result:
CytoDyn Inc. (CYDY), a biotechnology company, is developing leronlimab, a CCR5 antagonist, and has announced encouraging survival outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab, with some patients surviving more than 36 months after treatment.
Nice @ 1st time seeing that....
Come on May !!
CytoDyn Inc. (CYDY), a biotechnology company, is developing leronlimab, a CCR5 antagonist, and has announced encouraging survival outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab, with some patients surviving more than 36 months after treatment.
Nice @ 1st time seeing that....
Come on May !!
(7)
(0)Scroll down for more posts ▼
